Literature DB >> 26715876

Treatment patterns among Canadian men diagnosed with localized low-risk prostate cancer.

C Sandoval1, K Tran1, R Rahal1, G Porter2, S Fung1, C Louzado1, J Liu1, H Bryant3.   

Abstract

In general, guideline-recommended treatment options for men with low-risk prostate cancer (pca) include active surveillance, radical prostatectomy, and external-beam radiation therapy or brachytherapy. Because of the concern about overdiagnosis and consequent overtreatment of pca, patients with low-risk disease are increasingly being managed with active surveillance. Using data from six provincial cancer registries, we examined treatment patterns within a year of a diagnosis of localized low-risk pca, and we assessed differences by age. Of patients diagnosed in 2010 in four of the six reporting provinces, most received surgery or radiation therapy within 1 year of diagnosis. Depending on the province, either surgery or radiation therapy was the most commonly used primary treatment. In the other two provinces, most patients had no record of treatment within a year of diagnosis. Examining treatment patterns by age demonstrated a lesser likelihood of receiving surgery or radiation therapy within 1 year of diagnosis among men more than 75 years of age than among men 75 years of age or younger (no record of treatment in 69.1% and 46.3% respectively). In conclusion, we observed interprovincial and age-specific variations in the patterns of care for men with low-risk pca. The findings presented in this report are intended to identify opportunities for improvement in clinical practice that could lead to improved care and experience.

Entities:  

Keywords:  Low-risk prostate cancer; active surveillance; observation; older men; treatment

Year:  2015        PMID: 26715876      PMCID: PMC4687664          DOI: 10.3747/co.22.2895

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  6 in total

1.  Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach.

Authors:  M Kerba; Qun Miao; J Zhang-Salomons; W Mackillop
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-08-24       Impact factor: 4.126

2.  Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.

Authors:  Stephen Overholser; Matthew Nielsen; Kathleen Torkko; Daniel Cwilka; Brandi Weaver; Xiaoyu Shi; Robin J Leach; Javier Hernandez; Tim Huang; Ian M Thompson; Ian M Thompson
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

3.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Authors:  Laurence Klotz; Danny Vesprini; Perakaa Sethukavalan; Vibhuti Jethava; Liying Zhang; Suneil Jain; Toshihiro Yamamoto; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

4.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

Authors:  Pim J van Leeuwen; David Connolly; Anna Gavin; Monique J Roobol; Amanda Black; Chris H Bangma; Fritz H Schröder
Journal:  Eur J Cancer       Date:  2009-10-03       Impact factor: 9.162

  6 in total
  2 in total

1.  Active treatment in low-risk prostate cancer: a population-based study.

Authors:  S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

2.  Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.

Authors:  Christopher J D Wallis; Shawn Malone; Ilias Cagiannos; Scott C Morgan; Robert J Hamilton; Naveen S Basappa; Cristiano Ferrario; Geoffrey T Gotto; Ricardo Fernandes; Tamim Niazi; Krista L Noonan; Fred Saad; Sebastien J Hotte; Huong Hew; Katherine F Y Chan; Laura Park Wyllie; Bobby Shayegan
Journal:  JNCI Cancer Spectr       Date:  2021-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.